Gain Therapeutics (NASDAQ:GANX – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.16, Fidelity Earnings reports. Gain Therapeutics had a negative return on equity of 33.77% and a negative net margin of 8,470.12%. Shares of […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest in February. As of February 28th, there was short interest totalling 37,500 shares, a decline of 42.0% from the February 13th total of 64,700 shares. Based on an average trading volume of 55,100 shares, the days-to-cover ratio is […]
Initial public offerings scheduled to debut next week
March 12, 2021
FacebookTwitterEmail
NEW YORK (AP) The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
Week of March 15
Duckhorn Portfolio (The) - 20 million shares, priced $14-$16, managed by JP Morgan/Credit Suisse. Proposed NYSE symbol NAPA. Business: Produces and distributes luxury wine in North America.
Gain Therapeutics - Bethesda, Md., 3.6 million shares, priced $10-$12, managed by BTIG/Oppenheimer & Co. Proposed Nasdaq symbol GANX. Business: Preclinical biotech developing small molecule therapies for lysosomal storage.
Jowell Global - Shanghai, China, 3.7 million shares, priced at $7, managed by Network 1 Financial Securities. Proposed Nasdaq symbol JWEL. Business: Operates an e-commerce platform for cosmetics and health products in China.